Eli Lilly
-
Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease
Congratulations to Eli Lilly and AD patients!
-
Radionetics Oncology Enters Into Strategic Agreement With Lilly on its proprietary GPCR targeting small molecule radiopharmaceuticals
Warmest congratulations to Eli Lilly and Radionetics Oncology!
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content